BridgeMD
Tests treatment safety and results for Neck Pain
Official title Efficacy of Adding Greater Occipital Nerve Block to Trigger Point Injection in Patients With Neck Pain
ClinicalTrials.gov ID: NCT07058636
What this study is testing
What is 2% Lidocaine HCl + saline?
2% Lidocaine HCl + saline is an investigational medicine, given as an once-weekly injectable medicine, being studied as a potential treatment for neck pain.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Study Title: Evaluation of the Effectiveness of Adding Greater Occipital Nerve Block to Trigger Point Injection in Patients with Neck Pain Due to Upper Trapezius Trigger Points: A Single-Blind Randomized Controlled Trial Purpose of the Study: This study aims to evaluate whether adding a Greater Occipital Nerve (GON) block to the standard trigger point injection treatment provides better pain relief and improves daily function in patients with neck pain caused by trigger points in the upper trapezius muscle. Trigger points are small, sensitive spots in muscles that can cause significant pain and discomfort.
- Time commitment: about 12 months
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 65
You may be able to join if
- Patients aged between 18 and 65 years.
- Diagnosed with myofascial pain syndrome (MPS) based on the major and minor criteria described by Travell and Simons (a diagnosis requires all 5 major...
- Presence of active trigger points in the upper trapezius muscle.
- Patients with neck pain lasting longer than 3 months.
- Pain intensity of ≥5 on the Visual Analog Scale (VAS).
You likely can't join if
- Elderly, pediatric, pregnant, postpartum, or breastfeeding individuals; patients in intensive care; unconscious individuals; or legally incapacitated...
- Known allergy to local anesthetics used in trigger point injection (e.g., lidocaine, bupivacaine) or to other drugs used (e.g., corticosteroids).
- Patients with bleeding disorders (e.g., hemophilia, thrombocytopenia) or those currently on anticoagulant therapy.
- Presence of active infection at or near the injection site, or any systemic infection; impaired skin integrity.
- Patients with psychiatric disorders that may interfere with treatment response or affect study outcomes.
- Patients with severe neurological or cardiovascular disorders, or with uncontrolled diabetes.
See the full eligibility criteria
- Patients aged between 18 and 65 years.
- Diagnosed with myofascial pain syndrome (MPS) based on the major and minor criteria described by Travell and Simons (a diagnosis requires all 5 major and at least 1 minor criterion)
- Presence of active trigger points in the upper trapezius muscle.
- Patients with neck pain lasting longer than 3 months.
- Pain intensity of ≥5 on the Visual Analog Scale (VAS).
- Elderly, pediatric, pregnant, postpartum, or breastfeeding individuals; patients in intensive care; unconscious individuals; or legally incapacitated persons.
- Known allergy to local anesthetics used in trigger point injection (e.g., lidocaine, bupivacaine) or to other drugs used (e.g., corticosteroids).
- Patients with bleeding disorders (e.g., hemophilia, thrombocytopenia) or those currently on anticoagulant therapy.
- Presence of active infection at or near the injection site, or any systemic infection; impaired skin integrity.
- Patients with psychiatric disorders that may interfere with treatment response or affect study outcomes.
- Patients with severe neurological or cardiovascular disorders, or with uncontrolled diabetes.
- Patients with cervical disc pathologies with radiculopathy.
- History of receiving shoulder injection, trigger point injection, dry needling, manual therapy, or electrotherapy within the past 3 months.
- History of cervical or shoulder surgery.
- Patients diagnosed with adhesive capsulitis, rotator cuff tendinopathy, or shoulder impingement syndrome.
- Diagnosis of fibromyalgia.
- Presence of active trigger points in other back muscles.
The study team makes the final eligibility decision.
Where it's taking place
- Ankara, Turkey (Türkiye)
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The study runs about 12 months per participant, based on its public description. The team confirms the exact schedule and number of visits before you enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 65 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Ankara, Turkey (Türkiye). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.